Ionis Pharmaceuticals (IONS) said late Thursday the US Food and Drug Administration has approved Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.
The syndrome is genetic form of severe hypertriglyceridemia that can result in potentially life-threatening conditions, the company said.
The drug, also called olezarsen, was approved based on data from a phase 3 clinical trial in which it reduced triglyceride levels 42.5% from baseline to six months, the company said.
Shares of the company were up 7.5% in Friday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments